Stem Cell Transplant + Polatuzumab for Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you must not have received myelosuppressive chemotherapy within 2 weeks (or 4 weeks for certain drugs) before starting the study, and at least 7 days must have passed since completing therapy with a biologic agent.
Is the combination of Stem Cell Transplant and Polatuzumab Vedotin safe for humans?
Polatuzumab Vedotin, also known as Polivy, has been studied in several clinical trials for treating certain types of lymphoma, and it generally shows a low risk of causing immune reactions in patients. It has been approved by the FDA for use in combination with other drugs for specific lymphoma cases, indicating that it has an acceptable safety profile when used as directed.12345
How is the drug Polatuzumab Vedotin used in lymphoma treatment unique?
Polatuzumab Vedotin is unique because it is an antibody-drug conjugate that specifically targets CD79b on B cells, delivering a potent anti-cancer agent directly to these cells, which helps to inhibit their division and induce cell death. This targeted approach is different from traditional chemotherapy, which affects both cancerous and healthy cells.24567
What data supports the effectiveness of the drug Polatuzumab Vedotin (Polivy) for lymphoma?
Polatuzumab Vedotin has shown significant activity in treating diffuse large B-cell lymphoma, especially when combined with other drugs like rituximab, and is FDA-approved for relapsed or refractory cases. It targets a specific protein on B cells and has been effective in both previously untreated and relapsed/refractory cases.368910
Who Is on the Research Team?
Aliza Gardenswartz, MD
Principal Investigator
New York Medical College
Are You a Good Fit for This Trial?
This trial is for patients with various types of B-cell and Hodgkin Lymphoma who have had a relapse or are not responding well to initial treatments. They must be over 16, have a life expectancy greater than 6 weeks, and show adequate organ function. Patients can't join if they're pregnant, breastfeeding, have severe neuropathy, active CNS lymphoma, uncontrolled infections or are using other investigational drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Conditioning and Autologous Stem Cell Transplantation
Patients receive one of two conditioning regimens (BEAM or CBV) before undergoing autologous stem cell transplantation (ASCT)
Polatuzumab Vedotin Therapy
Patients receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses
Follow-up
Patients are monitored every 4 months for about 2 years to assess safety and effectiveness
What Are the Treatments Tested in This Trial?
Interventions
- Polatuzumab Vedotin
Find a Clinic Near You
Who Is Running the Clinical Trial?
New York Medical College
Lead Sponsor